<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919399</url>
  </required_header>
  <id_info>
    <org_study_id>01 SEIN 03</org_study_id>
    <nct_id>NCT00919399</nct_id>
  </id_info>
  <brief_title>Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant</brief_title>
  <acronym>TAMARO</acronym>
  <official_title>Phase II Study Evaluating the Effectiveness of the Exemestane (Aromasin) With Tamoxifen on the Rate of Clinical Response Menopausal in Patients With Locally Advanced Breast Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PHARMACIA SAS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II non-randomized, open, uncontrolled and bi-centric study of hormonal
      induction by exemestane (Aromasin) + tamoxifen to evaluate the effectiveness of exemestane
      (Aromasin) with tamoxifen on the rate of clinical response menopausal in patients with tumors
      of locally advanced breast. Hormone therapy will be administered at a dose of 25mg/day for
      exemestane and 20 mg / day for 4 months for tamoxifen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the objective response rate (complete response and partial response)</measure>
    <time_frame>June 2006</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic interaction between Exemestane and Tamoxifen</measure>
    <time_frame>june 2006</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>25mg a day during 4 months</description>
    <other_name>AROMASINE®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen</intervention_name>
    <description>One 20 mg tablet a day started 1 week after the first Aromasine intake</description>
    <other_name>KESSAR®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast cancer histologically proven by a 14 G or 16 G micro-biopsy to have
             confirmation of the diagnosis, evaluation histology prognosis grade, hormone receptors
             and to obtain a sample for the study of biological factors.

          -  Menopausal patients as defined as follows:

               -  Natural menopause &gt;= 1 year, or

               -  Surgical ovariectomy.

          -  T unilateral tumor&gt; 3 cm, N 1-2, M0 or M +, non-inflammatory.

          -  Hormone receptor positive. RE positive or PR positive with histochemical technique (+
             10% of cells express the receptor)

          -  No previous treatment of the disease by chemotherapy, hormone therapy, surgery or
             radiotherapy. Discontinuation of replacement therapy of menopause for at least 1 month

          -  Age&gt;= 60 years

          -  Evaluable disease

          -  Performance Status &lt;= 2

          -  Biological function using the following criteria:

               -  neutrophils &gt;= 2.10E9 / l,

               -  Platelets&gt; = 100.10E9 / l,

               -  Hemoglobin&gt; = 10 g / dl,

               -  Creatinine &lt;= 1.5 x upper normal,

               -  Total bilirubin &lt;= 1.25 x the upper normal

               -  Transaminases (AST and ALT) &lt;= 1.5 x upper normal,

               -  Alkaline phosphatase &lt;= 2.5 x upper normal.

          -  Cardiac Function: electrocardiogram (ECG) normal.

          -  Signed written consent before any procedure related to the study.

        Exclusion Criteria:

          -  Men

          -  Non Menopausal Patients

          -  Patients with hormone receptor negative: PR- and RE -

          -  Contra-indication to anti-estrogens (risk thrombi arteria)

          -  Tumor &lt;3 cm operable

          -  Tumor inflammatory T4d (PEV 2 or 3).

          -  Extensive hepatic lesions (&gt; 1 / 3 of liver volume)

          -  Uncontrolled cardiac disease such as angina, congestive heart failure, or arrhythmia
             requiring medical treatment or history of myocardial infarction within 3 months
             before.

          -  History of cancer except skin cancer and basal cell cancer in situ of the cervix (a
             contralateral breast cancer had been no systemic treatment will be admitted).

          -  Chronic diseases (somatic or psychiatric) in poor prognosis.

          -  Patients who for reasons of family, social, geographical or psychological can not be
             followed properly.

          -  Patients under law protection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henri ROCHE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Toulouse Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <last_update_submitted>June 11, 2009</last_update_submitted>
  <last_update_submitted_qc>June 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Henri Roché - Professor</name_title>
    <organization>Institut Claudius Regaud</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>locally advanced</keyword>
  <keyword>Menopausal patient</keyword>
  <keyword>aromasin</keyword>
  <keyword>tamoxifen</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

